An IgG-induced neutrophil activation pathway contributes to human drug-induced anaphylaxis.


Journal

Science translational medicine
ISSN: 1946-6242
Titre abrégé: Sci Transl Med
Pays: United States
ID NLM: 101505086

Informations de publication

Date de publication:
10 07 2019
Historique:
received: 21 02 2018
revised: 21 12 2018
accepted: 21 05 2019
entrez: 12 7 2019
pubmed: 12 7 2019
medline: 25 7 2020
Statut: ppublish

Résumé

Anaphylaxis is a systemic acute hypersensitivity reaction that is considered to depend on allergen-specific immunoglobulin E (IgE) antibodies and histamine release by mast cells and basophils. Nevertheless, allergen-specific IgG antibodies have been proposed to contribute when the allergen is an abundant circulating large molecule, e.g., after infusions of therapeutic antibodies or dextran. Data from animal models demonstrate a pathway involving platelet-activating factor (PAF) release by monocytes/macrophages and neutrophils activated via their Fc gamma receptors (FcγRs). We hypothesized that such a pathway may also apply to small drugs and could be responsible for non-IgE-mediated anaphylaxis and influence anaphylaxis severity in humans. We prospectively conducted a multicentric study of 86 patients with suspected anaphylaxis to neuromuscular-blocking agents (NMBAs) during general anesthesia and 86 matched controls. We found that concentrations of anti-NMBA IgG and markers of FcγR activation, PAF release, and neutrophil activation correlated with anaphylaxis severity. Neutrophils underwent degranulation and NETosis early after anaphylaxis onset, and plasma-purified anti-NMBA IgG triggered neutrophil activation ex vivo in the presence of NMBA. Neutrophil activation could also be observed in patients lacking evidence of classical IgE-dependent anaphylaxis. This study supports the existence of an IgG-neutrophil pathway in human NMBA-induced anaphylaxis, which may aggravate anaphylaxis in combination with the IgE pathway or underlie anaphylaxis in the absence of specific IgE. These results reconcile clinical and experimental data on the role of antibody classes in anaphylaxis and could inform diagnostic approaches to NMBA-induced acute hypersensitivity reactions.

Identifiants

pubmed: 31292264
pii: 11/500/eaat1479
doi: 10.1126/scitranslmed.aat1479
pii:
doi:

Substances chimiques

Biomarkers 0
Immunoglobulin G 0
Neuromuscular Blocking Agents 0
Platelet Activating Factor 0
Receptors, IgG 0
Immunoglobulin E 37341-29-0

Types de publication

Journal Article Multicenter Study Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

Copyright © 2019 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works.

Auteurs

Friederike Jönsson (F)

Unit of Antibodies in Therapy and Pathology, Institut Pasteur, UMR 1222 INSERM, 75015 Paris, France.

Luc de Chaisemartin (L)

Département d'Immunologie et d'Hématologie, UF Auto-immunité et Hypersensibilités, HUPNVS, Hôpital Bichat, 75018 Paris, France.
Inflammation Chimiokines et Immunopathologie, INSERM UMR S996, Faculté de Pharmacie, Université Paris-Sud, Université Paris-Saclay, 92290 Châtenay-Malabry, France.

Vanessa Granger (V)

Département d'Immunologie et d'Hématologie, UF Auto-immunité et Hypersensibilités, HUPNVS, Hôpital Bichat, 75018 Paris, France.
Inflammation Chimiokines et Immunopathologie, INSERM UMR S996, Faculté de Pharmacie, Université Paris-Sud, Université Paris-Saclay, 92290 Châtenay-Malabry, France.

Aurélie Gouel-Chéron (A)

Unit of Antibodies in Therapy and Pathology, Institut Pasteur, UMR 1222 INSERM, 75015 Paris, France.
AP-HP, Hôpital Bichat, Département d'Anesthésie-Réanimation, HUPNVS, 75018 Paris, France.

Caitlin M Gillis (CM)

Unit of Antibodies in Therapy and Pathology, Institut Pasteur, UMR 1222 INSERM, 75015 Paris, France.

Qianqian Zhu (Q)

Unit of Antibodies in Therapy and Pathology, Institut Pasteur, UMR 1222 INSERM, 75015 Paris, France.
Inflammation Chimiokines et Immunopathologie, INSERM UMR S996, Faculté de Pharmacie, Université Paris-Sud, Université Paris-Saclay, 92290 Châtenay-Malabry, France.

Fadia Dib (F)

AP-HP, Hôpital Bichat, Department of Epidemiology and Clinical Research, INSERM, 75018 Paris, France.

Pascale Nicaise-Roland (P)

Département d'Immunologie et d'Hématologie, UF Auto-immunité et Hypersensibilités, HUPNVS, Hôpital Bichat, 75018 Paris, France.

Christelle Ganneau (C)

Unité de Chimie des Biomolécules, Institut Pasteur, UMR 3523 CNRS, 75015 Paris, France.

Maria Hurtado-Nedelec (M)

Département d'Immunologie et d'Hématologie, UF Dysfonctionnements Immunitaires, HUPNVS, Hôpital Bichat, 75018 Paris, France.

Catherine Paugam-Burtz (C)

Département d'Anesthésie-Réanimation, Hôpital Beaujon, AP-HP, 92110 Clichy, France.
Université Paris Diderot, 92110 Paris, France.

Skander Necib (S)

Département d'Anesthésie-Réanimation, Hôpital Beaujon, AP-HP, 92110 Clichy, France.
Université Paris Diderot, 92110 Paris, France.

Hawa Keita-Meyer (H)

Service d'anesthésie, Hôpital Louis Mourier, AP-HP, 92700 Colombes, France.
Université Paris Diderot, Sorbonne Paris Cité, EA Recherche Clinique coordonnée ville-hôpital, Méthodologies et Société (REMES), 75010 Paris, France.

Matthieu Le Dorze (M)

Département d'Anesthésie-Réanimation, Hôpital Lariboisière, AP-HP, 75010 Paris, France.

Bernard Cholley (B)

Service d'Anesthésie-Réanimation, Hôpital Européen Georges Pompidou, AP-HP, UMR 1140 INSERM, 75015 Paris, France.
Université Paris Descartes, Sorbonne Paris Cité, 75006 Paris, France.

Olivier Langeron (O)

Department of Anesthesia and Critical Care, Hôpital Pitié Salpêtrière, AP-HP, Sorbonne Université, 75013 Paris, France.
Infection and Epidemiology Department, Institut Pasteur Human Histopathology and Animal Models Unit, 75015 Paris, France.

Laurent Jacob (L)

Département d'Anesthésie-Réanimation, Hôpital Saint Louis, AP-HP, 75010 Paris, France.

Benoit Plaud (B)

Département d'Anesthésie-Réanimation, Hôpital Saint Louis, AP-HP, 75010 Paris, France.

Marc Fischler (M)

Service d'Anesthésie, Hôpital Foch, 92150 Suresnes, France.

Caroline Sauvan (C)

AP-HP, Hôpital Bichat, Service de Pneumologie A, HUPNVS, 75018 Paris, France.

Marie-Thérèse Guinnepain (MT)

Hôpital Foch, Service de médecine interne, 92150 Suresnes, France.

Philippe Montravers (P)

AP-HP, Hôpital Bichat, Département d'Anesthésie-Réanimation, HUPNVS, 75018 Paris, France.
INSERM 1152, DHU FIRE, Labex Inflamex, Université Paris Diderot Paris 7, 75018 Paris, France.

Michel Aubier (M)

AP-HP, Hôpital Bichat, Service de Pneumologie A, HUPNVS, 75018 Paris, France.
INSERM 1152, DHU FIRE, Labex Inflamex, Université Paris Diderot Paris 7, 75018 Paris, France.

Sylvie Bay (S)

Unité de Chimie des Biomolécules, Institut Pasteur, UMR 3523 CNRS, 75015 Paris, France.

Catherine Neukirch (C)

AP-HP, Hôpital Bichat, Service de Pneumologie A, HUPNVS, 75018 Paris, France.
INSERM 1152, DHU FIRE, Labex Inflamex, Université Paris Diderot Paris 7, 75018 Paris, France.

Florence Tubach (F)

Sorbonne Université, INSERM, Institut Pierre Louis d'Epidémiologie et de Santé Publique, PEPITES, AP-HP, Hôpitaux Universitaires Pitié Salpêtrière-Charles Foix, Département Biostatistique Santé Publique et Information Médicale, Centre de Pharmacoépidémiologie (Cephepi), CIC-1421, 75013 Paris, France.

Dan Longrois (D)

Département d'Immunologie et d'Hématologie, UF Auto-immunité et Hypersensibilités, HUPNVS, Hôpital Bichat, 75018 Paris, France.
AP-HP, Hôpital Bichat, Département d'Anesthésie-Réanimation, HUPNVS, 75018 Paris, France.

Sylvie Chollet-Martin (S)

Département d'Immunologie et d'Hématologie, UF Auto-immunité et Hypersensibilités, HUPNVS, Hôpital Bichat, 75018 Paris, France. bruhns@pasteur.fr sylvie.martin2@aphp.fr.
Inflammation Chimiokines et Immunopathologie, INSERM UMR S996, Faculté de Pharmacie, Université Paris-Sud, Université Paris-Saclay, 92290 Châtenay-Malabry, France.

Pierre Bruhns (P)

Unit of Antibodies in Therapy and Pathology, Institut Pasteur, UMR 1222 INSERM, 75015 Paris, France. bruhns@pasteur.fr sylvie.martin2@aphp.fr.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH